Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies

J.S.A. Stringer, M. Sinkala, D.J. Rouse, R.L. Goldenberg and S.H. Vermund

American Journal of Public Health, 2002, vol. 92, issue 3, 365-366

Abstract: Objectives. This study evaluated the validity of concerns about the toxicity of nevirapine (NVP) that have delayed its implementation as a perinatal HIV prevention strategy. Methods. A decision analysis model compared 3 strategies: single-dose NVP, short-course zidovudine (ZDV), and no intervention. Results. NVP would prevent more deaths than ZDV and no intervention as long as the rate of NVP toxicity did not exceed, respectively, 9 times that observed in the earlier NVP clinical trial and 42 times that observed in the clinical trial. NVP would be economically preferable to ZDV as long as the rate of toxicity did not exceed 22 times that observed in the clinical trial. Conclusions. Field implementation of NVP should not be delayed by concerns about its toxicity.

Date: 2002
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:2002:92:3:365-366_6

Access Statistics for this article

American Journal of Public Health is currently edited by Alfredo Morabia

More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().